Abstract Library

#4477 Stable tumoural response to stereotactic body radiotherapy in well-differentiated metastatic small intestine neuroendocrine tumour

Introduction: Over half of patients with Neuroendocrine tumours (NET) have unresectable or metastatic disease. SSA y PRRT are successful targeted therapy to symptoms relief and stabilise disease. Otherwise, there are emerging options of radiotherapy including hypofractionation or stereotactic body radiotherapy. The clinical evidence of radiotherapy in NEN is scarce, and there is limited published data.

Conference:

Presenting Author: Florez A

Authors: Sanabria D, Florez A,

Keywords: Neuroendocrine, Tumour, metastatic,

#4342 A real-world retrospective analysis to evaluate the efficacy and safety of surufatinib in the treatment of unresectable, locally advanced or metastatic neuroendocrine neoplasms in China

Introduction: The incidence of NENs is on the rise. In NECs, research on surufatinib is still scarce.

Conference:

Presenting Author:

Authors: Liu S, Zhang L, Liu B, Liu Q,

Keywords: neuroendocrine neoplasm, surufatinib, neuroendocrine carcinoma, neuroendocrine tumour, real-world study,

#4290 TB-161-Dotatate and Lu-177-Dotatate as a tandem therapy

Introduction: Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that frequently express cell-membrane specific peptide receptors, such as somatostatin receptors.

Conference:

Presenting Author:

Authors: Hambapersad T, Maharaj M,

Keywords: TB-161-Dotatate, Lu-177-Dotatate, Tandem,

#3739 Local tumor control in patients with neuroendocrine neoplasms treated with stereotactic ablative radiotherapy (SBRT)

Introduction: Neuroendocrine neoplasms (NEN) represent a diverse group of malignancies. Anatomic origin, histology and biological behaviour vary extensively. The treatment armamentarium includes surgery (first choice when possible), systemic therapy and localised treatment modalities. The role of radiotherapy is not yet established, but studies indicate that local tumor control (LTC) can be achieved by high-dose radiotherapy. Stereotactic ablative radiotherapy (SBRT) is high doses of radiation delivered to a small target, with potential of achieving local tumor control.

Conference:

Presenting Author:

Authors: Nygaard Dowler A, Aggerholm Pedersen N, Knap Marquard M, Dam G, Tabaksblat E,

Keywords: neuroendocrine, stereotactic radiotherapy, sbrt, local control,

#3483 A phase II single arm interventional trial evaluating the activity and safety of combination between CABOzantinib and TEMozolomide (TMZ) in lung and GEP-NENs progressive after SSAs, everolimus, sunitinib or PRRT-CABOTEM

Introduction: Cabozantinib (Cbz), a tyrosine kinase inhibitor, and Temozolomide (TMZ), an alkylating agent, show relevant clinical implications in neuroendocrine neoplasms (NENS). In glioma patients, the combination of Cbz and TMZ was well tolerated even with the addition of radiotherapy. It is possible to hypothesize a synergistic combination of Cbz and TMZ. Cbz, through the inhibition of the c-MET pathway, could enhance the sensitivity of NENs to TMZ. In addition, the intermittent metronomic schedule of TMZ has a proven anti-angiogenic activity that could be additive and/or enhance the anti-angiogenic effect of Cbz.

Conference:

Presenting Author:

Authors: Clemente O, Starita N, Cives M, Bracigliano A, Badalamenti G,

Keywords: neuroendocrine, Cabozantinb, Temozolomide, treatment, clinical trial, NEN,